Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  MRI test could predict kidney cancer patients who may benefit from anti-vascular therapy

MRI test could predict kidney cancer patients who may benefit from anti-vascular therapy

by | Aug 18, 2017 | Kidney Cancer News | 0 comments

A magnetic resonance imaging (MRI) test that measures the volume of blood in tumours could help select which patients will benefit from drugs that block blood vessel growth, a new study shows.
In a study published in the journal Cancer Research, researchers have also provided intriguing new clues about how cancers become resistant to such drugs.
Scientists at The Institute of Cancer Research investigated a type of magnetic resonance imaging technology called susceptibility contrast MRI to measure blood volume in renal cell carcinomas – a type of kidney cancer.
In the study the team used the MRI scanning method to quantify the blood volume of kidney tumours transplanted in mice, before and after treatment with sunitinib – a drug that blocks blood vessel growth.
They found that the drug caused the volume of blood in tumours to drop by an average of 70%, while their overall size remained the same.
The drop in tumour blood volume caused by sunitinib was linked with a decrease in the number of blood vessels in the tumours.
Tumours with the largest volume of blood to start with had the greatest drop in blood volume and the best response to treatment with sunitinib, the study showed.

Drugs that block blood vessel growth in tumours

The findings point to quantitation of blood volume as a new, non-invasive measure of response to sunitinib – and possibly also other drugs that block blood vessel growth in tumours.
In the future, measuring tumour blood volume could help identify patients with kidney cancer who would be most likely to benefit from treatment with sunitinib.
Intriguingly, the researchers also found that blood volume remained suppressed in tumours that had stopped responding to sunitinib, and vessels did not grow back.
This suggests that in sunitinib-resistant tumours, other mechanisms aside from new blood vessel growth are at work to allow the tumour to continue growing.
You can read the full article on the Institute of Cancer Research site here

<a href="" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.